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Abstract 
Background: As new lymphatic filariasis infections are eliminated through mass chemotherapy, previously affected 
individuals are left with the sequellae, especially chronic progressive lymphoedema. Currently this is managed by 
careful attention to limb hygiene to prevent infection. Studies over the past 15 years have suggested that the incorpo‑
ration of doxycycline treatment may arrest or even reverse progression of lymphoedema. Most of this work has been 
observational or based on small studies, and if this intervention is effective, studies need to be conducted on a larger 
scale and under diverse geographical and social conditions before it can be incorporated into treatment policy.
Methods/Design: The double‑blind, placebo‑controlled study was designed to investigate the impact of six weeks 
treatment with doxycycline added to standard limb hygiene on early stage filarial lymphoedema in five sites in Africa 
and the Indian subcontinent. One site in Cameroon is selected for studying lymphoedema in podoconiosis. Each 
site was individually powered with the potential to undertake a meta‑analysis on completion. Evaluation methods 
followed those used in Ghana in 2012 with additions resulting from advances in technology. The details of the core 
protocol and how it was varied to take account of differing situations at each of the sites are provided. The study will 
enrol up to 1800 patients and will complete in mid‑2021.
Conclusions: This paper provides details of what challenges were faced during its development and discusses 
the issues and how they were resolved. In particular, the reasons for inclusion of new technology and the problems 
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Background
In the late 20th century lymphatic filariasis, caused by 
infections with either Wuchereria bancrofti, Brugia 
malayi or B. timori, was causing significant morbidity 
in approximately 20–40 million people globally, with a 
further 100 million infected but clinically asymptomatic, 
and up to one billion at risk of infection [1]. The develop-
ment of annual combination treatment with albendazole 
together with either ivermectin or diethylcarbamazine 
and their deployment through mass community treat-
ment under the Global Programme for the Elimination 
of Lymphatic Filariasis (GPELF) in all endemic areas has 
meant that, some 20 years later, transmission has ceased 
in many areas [2]. Over the coming decade it is expected 
that the infection will be eliminated in most parts of the 
world. However, one of the sequelae of the infection is 
chronic lymphatic damage, and thus those who have 
chronic manifestations will continue to suffer the con-
sequences long after elimination of transmission and 
infection. Because of recurrent bacterial infections in the 
affected limbs, lymphatic damage becomes progressively 
worse, leading to the classical picture of elephantiasis. 
This can be controlled to some extent by assiduous atten-
tion to limb hygiene and use of topical and oral antibiot-
ics to control acute episodes of infection. Limb hygiene 
should be taught to all affected persons as part of the 
elimination programmes but only about 35% of affected 
patients are actively applying this approach [3, 4].
In the search for effective medicines that kill the adult 
worms (macrofilaricides), there has been considerable 
interest in the potential of doxycycline and related anti-
biotics to kill the endosymbiotic bacterium, Wolbachia, 
which is essential for the survival and reproduction of 
the adult worms. In several studies, it was observed that 
both actively infected patients with lymphoedema and 
patients who had extinct infections appeared to benefit 
from six weeks of doxycycline treatment [5, 6]. A small 
prospective study was therefore undertaken in Ghana by 
Mand and colleagues [7] which compared patients with 
lymphoedema treated with either doxycycline, amoxi-
cillin or placebo and followed the progress of their lym-
phoedema over a 24-month period after treatment. While 
there was a measurable improvement in the assessments 
in doxycycline-treated patients, those treated with either 
amoxicillin or placebo showed progression. This outcome 
was of considerable interest, since it suggested that active 
hygiene measures combined with doxycycline could pro-
vide greater benefit to patients with established lymphoe-
dema, thereby reducing the morbidity associated in those 
already affected. This could be through the antimicrobial 
effects of doxycycline reducing chronic infection or pos-
sibly through the additional anti-inflammatory effects of 
doxycycline [8]. Since most patients will have inactive 
disease, either because of MDA or the macrofilaria have 
died, an effect via Wolbachia killing seems unlikely.
The Mand study was small, with only 100 participants 
(40 in the doxycycline arm) completing all evaluations 
[7]. Changes to the advice on the management of lym-
phoedema subjects would require confirmation of these 
findings with larger numbers distributed more widely 
geographically and including patients with Brugia infec-
tions. This paper presents the design and implementation 
of a study to provide these larger numbers.
Following the publication of the Mand study, two sepa-
rate groups, the University of Bonn (UBonn) who con-
ducted the original study, and the Task Force for Global 
Health (TFGH) in Atlanta, USA, began to develop plans 
to repeat the study with larger sample sizes to be con-
ducted in several different geographical locations. Both 
groups initially intended to conduct the studies using 
Mand protocol design but with larger numbers and a 
double blind, placebo-controlled design. The two groups 
separately sought funding for their plans; eventually 
UBonn secured funding as part of the TAKeOFF project 
encountered with the supply of drugs for the studies are described in detail. By making these details available, it is 
hoped that the study protocol will help others interested in improving treatment for filarial lymphoedema in the 
design of future studies.
Trial registration India: Clintrials.gov. NCT02929121 registered 10 Oct 2016: https ://clini caltr ials.gov/ct2/show/NCT02 
92912 1
Mali: Clintrials.gov. NCT02927496 registered 7 Oct 2016: https ://clini caltr ials.gov/ct2/show/NCT02 92749 
Sri Lanka: Clintrials.gov. NCT02929134 registered 10 Oct 2016: https ://clini caltr ials.gov/ct2/show/NCT02 92913 4
Ghana: ISRCTN. 14042737 registered 10 July 2017: https ://doi.org/10.1186/ISRCT N1404 2737
Tanzania: ISRCTN. 65756724 registered 21 July 2017: https ://doi.org/10.1186/ISRCT N6575 6724
Cameroon: ISRCTN. 1181662 registered 25 July 2017: https ://doi.org/10.1186/ISRCT N1188 1662
Keywords: Lymphatic filariasis, Podoconiosis, Doxycycline, Hygiene, Lymphoedema, Clinical trial, Morbidity 
management
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(“Tackling the obstacles to fight filariasis and podoconio-
sis”) which is one out of five research networks for health 
innovations in sub-Saharan Africa funded by the German 
Federal Ministry of Education and Research (Bundesmin-
isterium für Bildung und Forschung - BMBF) (https ://
www.gesun dheit sfors chung -bmbf.de/en/resea rch-netwo 
rks-for-healt h-innov ation s-in-sub-sahar an-afric a-7694.
php); TFGH obtained funding from the United States 
Agency for International Development (USAID) (grant 
# AID-OAA-G-14-00008). Whereas the TFGH funding 
was specific for the lymphoedema study, the BMBF grant 
covered a further eight work packages associated with 
the management of morbidity and lymphoedema. The 
two groups were initially independent but came together 
in 2015, agreeing to conduct all studies to a single core 
protocol to maximise the impact of the work. Six country 
centres were included: Mali, Sri Lanka and Kerala, India 
(LEDoxy sites) were included under the TFGH grant; 
and Ghana, Tanzania and Cameroon (TAKeOFF) were 
included under the BMBF grant.
The primary aim of the studies was to determine 
whether a six-week course of doxycycline treatment, 
when added to standardised hygiene intervention, would 
arrest or reverse the progress of lymphoedema caused by 
lymphatic filariasis or in the case of Cameroon, caused 
by podoconiosis. Podoconiosis is a non-infectious tropi-
cal lymphoedema caused by long-term barefoot exposure 
to red clay soil derived from volcanic rocks [9] which has 
many characteristics similar to lymphatic filariasis and 
has been historically confused with it [10]. The probable 
mechanism is that the mineral particles penetrate the 
bare skin are engulfed by macrophages in the lower limb 
lymphatics to induce inflammatory responses [10].
In designing the protocol, it was agreed at the onset 
that the patient inclusion and exclusion criteria and the 
methods of measurement should follow those used in the 
original Mand study, thus replicating the patient popula-
tion and assessments as closely as possible. During devel-
opment of the protocol and early implementation of the 
studies several issues arose, and these are discussed.
Methods/Design
Overall study design
The protocol was designed to be a placebo-controlled 
comparison of the efficacy of doxycycline as an adjunc-
tive treatment for lymphoedema. All subjects were to 
receive training and implement the established regular 
hygiene measures used for the management of lymphoe-
dema defined in the GPELF Management Guidelines [11] 
and in addition received daily doxycycline or placebo for 
six weeks. It is unknown whether there would be vari-
ations in efficacy between geographical areas with W. 
bancrofti infection or in the case of India with B. malayi 
infection. Similarly, there are no data on the efficacy of 
doxycycline in podoconiosis. It was therefore decided to 
conduct six studies, each separately powered, but using 
the same core protocol.
Lymphoedema in lymphatic filariasis and podoconiosis 
is progressive, with intermittent infection and increas-
ing oedema and scarring, eventually resulting in perma-
nent changes in the lower limbs. However, symptoms and 
signs in the early stages are more likely to be reversible. 
Therefore, the core protocol focused on patients with 
early lymphoedema classified as being Dreyer stages 1 
through 3 [3] and the individual lymphatic filariasis stud-
ies enrolled patients in these categories. Additionally, 
it was decided that a small, unpowered investigation of 
the impact of intervention on lymphoedema stages 4–6 
should be included since data were lacking with advanced 
disease stage. The podoconiosis study was limited to per-
sons with stages 2 and 3 disease [12]. All patients within 
the study are followed for a total of 24 months.
Trial setting
The six trial sites had a proven history of lymphatic fila-
riasis or podoconiosis endemicity with a large population 
of patients with lymphoedema to facilitate recruitment. 
All sites were either rural villages or associated with small 
towns to facilitate treatment and follow-up. The locations 
of the study sites are provided in Table 1.
Trial supplies
Active and placebo doxycycline
Since this study was to be conducted double-blind, it was 
necessary to source active and placebo doxycycline and 
to package the drugs in an appropriate manner to facili-
tate treatment in rural settings. All elements of the supply, 
analysis, packaging and distribution are being undertaken 
by Piramal Healthcare Ltd, Morpeth, UK, a company 
with extensive experience in GMP production of clinical 
trial supplies. Piramal undertook an analysis of potential 
sources of active doxycycline formulations to determine 
the most appropriate manufacturer. Several different 
options were investigated, and doxycycline hydrochlo-
ride was rapidly discounted as an option as manufacturers 
with appropriate approvals was very limited. Examination 
of the alternate doxycycline hyclate suggested that both 
100 mg tablets and capsules were available, but that tab-
lets would be the easiest option to follow especially as the 
supplies would be used in tropical zones. Several differ-
ent manufacturers in the European Union were identified, 
and ultimately Remedica, Limassol, Cyprus, was chosen 
as the source. This was based on the ability to supply and 
the company experience in producing approved products 
for use by different international organizations. Placebo 
manufacture was undertaken by Piramal Healthcare Ltd, 
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since placebo was not available from the manufacturer of 
the active. In addition, Piramal undertook all packaging 
activity, producing both the blister beds and the second-
ary treatment packs in a GMP facility.
Blister treatment packs
The design of the blister packs had to accommodate 16 
tablets and to have space for labelling of blisters accord-
ing to the different country requirements. Additionally, 
because doxycycline is normally used at a lower dose 
(100 mg) in patients below 18 years of age or under 50 kg 
body weight, it was necessary for one blister strip to be 
removed for these patients. In two study sites (in Ghana 
and Tanzania) it was decided to also examine the efficacy 
of 100  mg doxycycline in a third arm since, if effective, 
this could ultimately reduce the cost and complexity of 
treatment. To maintain double-blind conditions, this 
approach required the packing of both active and pla-
cebo within a single blister bed with the ability to remove 
one set of tablets for those under 18 years or 50 kg body 
weight. The individual blister beds contained enough 
medication for one week together with additional tablets 
to allow for visit delays. The final design had two paral-
lel blister beds separated by a perforation and a third 
area for the label. Treatment packs were made contain-
ing 6 sets of blisters for the treatment of one patient for 
6  weeks. Treatments were produced for each study site 
according to separate pre-determined randomization 
lists for the main study group and for the advanced lym-
phoedema group.
Shipping supplies
Since antibiotics are relatively thermo-labile, all supplies 
were transferred to trial sites by air courier in 7-day tem-
perature-controlled gel packs with temperature logging. 
The logs indicated that all supplies were transferred to 
site within the prescribed storage limits for the product. 
On receipt at the trial sites, the supplies were transferred 
to temperature-controlled storage until required.
Trial governance
The studies are funded through TFGH by USAID and 
by the BMBF (TAKeOFF) and their conduct is overseen 
by two Coordinating Committees at the TFGH (Mali, 
Sri Lanka, India) and UBonn (Ghana, Tanzania, Cam-
eroon) which collaborate and share information on a 
regular basis. Separate Data Safety Monitoring Commit-
tees (DSMCs) comprised of independent scientists are 
established for each of the two groups of studies in order 
to monitor the safety aspects of the studies, and the data 
are shared quarterly (TFGH) or biannually (TAKeOFF). 
In cases where SAEs occurred, the information is shared 
immediately and evaluated by the PI, Safety Officer and 
the DSMC.
For the TFGH trials, the core protocol was approved 
by the Western Institutional Review Board (Olympia, 
Washington USA) and additionally by each site’s local 
Ethics Committee and/or National Ethics Review Board. 
For the TAKeOFF trials, the protocols were approved by 
the local Institutional Review Boards as well as by the 
Ghana FDA and Ghana Health Service, the Tanzania 
FDA, the CNERSH, Yaoundé, Cameroon and addition-
ally by the University of Bonn Ethics Committee and for 
Tanzania by the LMU Munich Ethics Committee. Min-
istry of Health/Ghana FDA/Tanzania FDA approval was 
obtained to permit import of drug supplies and other 
trial related materials. All study sites were individu-
ally registered on Clintrials.gov (Mali: NCT 02927496; 
Sri Lanka: NCT02929134; India: NCT 02929121) or 
ISRCTN (Ghana: 14042737; Tanzania: 65756724; Cam-
eroon: 11881662) and, if required, with local clinical trial 
Table 1 Trial sites
Programme Country Study sites Environment Principal investigator Based at
LEDoxy Sri Lanka Pohlena, Walgama and Madihe 
suburbs, Galle
Semi‑urban Professor Channa Yahathugoda Faculty of Medicine, University of 
Rahuna, Galle
Mali Sikasso and Koulikoro Rural Dr Yaya I Coulibaly International Center for Excellence 
in Research, (ICER‑Mali), Bamako
India Ambalappuzha and Cherthala 
Yaluks, Alappuzha, Kerala
Rural/Semi‑urban Professor T K Suma Filariasis Research Unit, Govt. T. D. 
Medical College Hospital Alap‑
puzha, Kerala
TAKeOFF Ghana Upper East Region: Kassena‑Nan‑
kana Eeast and West Districts
Rural Professor Alexander Yaw Debrah Kumasi Centre for Collaborative 
Research (KCCR), Kwame Nkru‑
mah University of Science and 
Technology (KNUST), Kumasi
Tanzania Lindi Region, Pwani Region Rural/Semi‑urban Dr Upendo Mwingira NIMR, Dar es Salaam
Cameroon North West Region Rural Professor Samuel Wanji Dept of Microbiology & Parasitol‑
ogy, University of Buea, SW State
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databases. Minor variations were required by the review 
boards before approval which did not impact on the 
overall core protocol. If appropriate and following con-
sultation with the trial sites, some of these were incorpo-
rated as protocol amendments in the core protocol and 
approved by the relevant review boards. The protocols 
for the LEDoxy (Additional file  1: Text S1), TAKeOFF 
filariasis (Additional file 2: Text S2) and TAKeOFF podo-
coniosis (Additional file 3: Text S3) studies are provided 
for reference.
Compliance with Good Clinical Practices (GCP) for 
Sri Lanka, Mali and India has been ensured by clinical 
monitors from FHI 360 (Durham, NC, USA) with visits 
at initiation, approximately one year after study initia-
tion and at study closure. In addition, visits are made by 
members from TFGH at intervals. Compliance with GCP 
at the TAKeOFF sites is provided by local monitors with 
visits at initiation followed by regular visits (biannually 
or annually) during the conduct of the trial. Addition-
ally, the Tanzanian trial site has been inspected by the 
Tanzania FDA and inspections of the Ghanaian trial site 
by the Ghana FDA and the Cameroon site by the Cam-
eroon National Ethics Committee are planned. A GCP 
workshop was organised by Ghana FDA and all scientists 
and clinicians working on the TAKeOFF Ghana project 
as well as those from Cameroon attended this workshop 
before starting recruitment of patients.
Study populations
The study aim is to evaluate the impact of doxycycline 
adjunctive treatment on lymphoedema, and therefore all 
subjects were required to have clinically evaluable dis-
ease. As a result of GPELF activities, most eligible sub-
jects at each site have been exposed to several annual 
rounds of treatment with either DEC plus albendazole 
or ivermectin plus albendazole and thus most did not 
have active lymphatic filarial infection. Lymphatic vessel 
damage occurs during infection but then evolves from an 
asymptomatic phase to overt and progressive lymphoe-
dema over many years even in the absence of active infec-
tion. The evolution of lymphoedema is well described and 
an agreed staging is accepted [3]. For the purposes of this 
study it was considered that the early stages (1–3) would 
be most likely to respond to additional treatment since 
the changes are potentially reversible as underlying fibro-
sis and scarring is not advanced. The primary focus of 
recruitment was therefore to screen and enrol subjects in 
stages 1–3. As previously noted, subjects who presented 
with more advanced lymphoedema (stages 4–6) could 
be enrolled to a blinded but unpowered cohort (LEDoxy 
sites) or as participants of a pilot trial with n = 60 per trial 
site (Ghana and Tanzania).
Since tetracyclines including doxycycline are known 
to cause damage to skeletal structures and teeth dur-
ing foetal development and through the first decade of 
life, all at-risk subjects were excluded from the study. 
Therefore, the minimal age for enrolment was set at 
14 years, thus avoiding the potential risk of skeletal 
and dental damage. In practice this should not impact 
the outcomes of the studies since, although lymphatic 
damage can occur in the first decade, evaluable clinical 
symptoms and signs do not generally become apparent 
until the middle of the second decade. Similarly, care 
had to be taken to avoid exposure of pregnant women 
to doxycycline, and women of childbearing poten-
tial were screened for pregnancy at enrolment, during 
and on completion of treatment. Pregnancy tests were 
additionally conducted in the TAKeOFF sites during 
the follow-up period since pregnancy can alter fluid 
load and might affect the lymphoedema measures. All 
women of childbearing potential were advised to avoid 
pregnancy during treatment. The full list of inclusion 
and exclusion criteria are provided in Table 2. Each of 
the TFGH study sites was required to enrol 100 sub-
jects with Stage 1–3 in each arm (placebo and doxycy-
cline); in the two TAKeOFF lymphatic filariasis studies 
120 subjects were enrolled in each of the three arms to 
allow for the comparison of three groups (placebo, low- 
and standard-dose doxycycline). Enrolment of subjects 
with stages 4–6 continued until the main study group 
(stages 1–3) was complete or until 50 subjects had been 
enrolled (LEDoxy sites). The TAKeOFF sites planned to 
enrol 60 patients per site to be in line with a sample size 
normally chosen for pilot-trials. The TAKeOFF podoc-
oniosis study in Cameroon entered 100 subjects in each 
of the standard 200  mg doxycycline and placebo arms 
comparable to the LEDoxy trials in Sri Lanka, Mali and 
India. The Cameroon study did not have an unpowered 
arm.
Evaluation criteria and methods
The Mand study in Ghana had evaluated lymphoedema 
in several different ways, and it was decided that all of 
these should be included in the current studies. The pri-
mary efficacy measure was to be the change in clinical 
staging (improve, no change, deteriorate) as in the Mand 
study, and these are described in Table 3 [7]. A similar set 
of stages are established for podoconiosis lymphoedema 
(Table 4) [12]. Staging can be subject to individual inter-
pretation by observers and therefore additional measures 
are included to provide support for the primary evalu-
ation. Classically, lymphoedema has been evaluated at 
predefined anatomical points on the affected limb(s), 
and this approach of measuring limb circumference 
was retained for these studies. Clinical observation is 
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also supported by digital photographs taken at the same 
time as the staging using a standardised methodology. 
Although producing standardised images is a problem 
under field conditions, it does provide evidence where 
discrepant observations are encountered.
Advances in mobile ultrasonography has permitted the 
measurement of skin and subcutaneous tissue thickness 
over the median and lateral malleolus which provides 
additional evidence of oedema in the affected limb [7]. 
While this technology has the potential to provide objec-
tive evidence of change, in practice it has proved to be 
quite time-consuming to conduct, and difficult to stand-
ardise, especially in the field. Therefore, ultrasonography 
Table 2 Inclusion and exclusion criteria
Study selection criteria Definition
Clinical inclusion criteria Age ≥ 14 years and ≤ 65 years
Male or non‑pregnant woman of childbearing‑potential using an approved, effective method of contraception before, 
during and for at least 2 weeks after the completion of the active intervention with doxycycline or placebo
Able to give informed consent/assent to participate in the trial
Resident in an LF endemic area for five years (> 2 years for TAKeOFF)
Body weight ≥ 40 kg
Lymphoedema of at least one limb Stage 1‑6 measured on a 7‑point scale. (Stage 2 or 3 for podoconiosis)
Ability to use established standardized methods of hygiene and effectively applying it prior to initiation of drug treat‑
ment
No evidence of severe or systemic co‑morbidities (except for features of filarial disease)
Normal laboratory profile (type of investigations and normal limits in the case of haematological abnormalities are 
site‑specific)
Consent to storage of blood samples for further study (site specific)
Negative pregnancy test
Clinical exclusion criteria No lymphoedema or lymphoedema stage 7
Age < 14 years or > 65 years
Body weight < 40 kg
Pregnant or breastfeeding women
Women of childbearing potential not using an agreed method of contraception
Clinical or laboratory evidence of hepatic or renal dysfunction or CNS disease
Alcohol or drug abuse
History of adverse reactions to doxycycline or other tetracyclines
Patient has any situation or condition that may interfere with participation in the study as judged by the clinical investi‑
gator
History of photosensitivity reactions after taking drugs
Concomitant medication with antacids containing aluminium, magnesium or sucralfate and not able to discontinue
Concomitant medication with other antibiotics than doxycycline and not able to discontinue
Concomitant medication with diuretics or sulfonylurea or coumarin
Laboratory exclusion criteria Haemoglobin < 8 g/dl
Neutrophil count < 1100/mm3
Platelet count < 100,000/mm3
Creatinine > 2 times upper limit of normal
AST (GOT), ALT (GPT), gamma‑GT > 2 times upper limit of normal
Positive urine pregnancy test
Table 3 Staging of lymphatic filariasis lymphoedema (after 
Dreyer (2002) [3])
Stage Definition
1 Swelling is reversible (goes away) overnight
2 Swelling is not reversible (does not go away)
3 Presence of shallow skin folds (base of fold can be seen with 
movement of leg)
4 Presence of skin knobs
5 Presence of deep skin folds (base of fold can only be seen if 
opened up)
6 Presence of “mossy lesions”. Warty looking epidermal skin lesions
7 Unable to care for self or perform daily activities
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has been retained for the LEDoxy trials but not for the 
TAKeOFF trials.
In lymphoedema not only does the circumference of 
the limb increase but also the limb volume. The classi-
cal approach for measuring volume is the use of water 
displacement where the limb is put into a container of 
known volume and water added to a defined level on 
the limb (usually a bony prominence), the volume being 
calculated by subtraction. This is clearly a cumbersome, 
although reasonably accurate measure but does not lend 
itself to field use. As a result, this method was not used 
in the present study but was replaced by a more efficient 
volume assessment technique.
This new technique was the development of a photo-
digital scanner (LymphaTech; Lymphatech.com) for 
limb volume measurement. The tool uses computerised 
infrared imaging captured on computer tablets to gener-
ate virtual 3D images of each limb that are used to cal-
culate the limb volume indirectly. This technology was in 
its early stages of validation when the study protocol was 
designed, but by the time the study was ready to start, it 
was advanced enough to be added alongside the other, 
traditional measures. Details of the methodology and 
validation have been published [13], and user protocols 
have advanced during the study as field experience has 
increased. The developers have continued to work closely 
with study investigators for training and monitoring the 
course of the study. More importantly, this new approach 
allows rapid image capture to accurately measure volume 
in real time, being a considerable advance on the tradi-
tional measures described above and still retained for 
these studies.
It is strongly held that secondary bacterial and fungal 
infections are important contributory elements to the 
development of lymphoedema and dermal changes: the 
inclusion of regular washing of the affected limb(s) in 
the WHO recommended basic package of care [11] is 
founded on this understanding. As these WHO recom-
mendations have been, appropriately, included in the 
present study, and as positive effects of washing on the 
clinical condition of the affected limbs are a potential 
confounding factor to the outcomes of our study, we have 
included an assessment of each patient’s adherence to 
washing as part of the study site procedures.
This assessment is divided into observations by the 
attendant care-giver as to (i) the cleanliness of the limb(s) 
(e.g. dirt on the skin, in skin folds, or on the toe nail bed); 
and (ii) a simple assessment of the condition of the skin 
of the limb (e.g. presence of open wounds, or cracks 
between the toes). Since items for washing (soap, bowls 
and towels, replenished as necessary) have been pro-
vided, each participant is asked to show that they still 
possess these items at each evaluation time. The presence 
of these items has been used previously as a useful sur-
rogate for compliance with washing [4, 11].
Study structure
For the LEDoxy sites all potential subjects are provided 
with information on the study design by study staff in 
the local languages and consent for screening (medi-
cal history, lymphoedema staging, laboratory tests and 
pregnancy tests for females) are obtained. Potential sub-
jects return in 1–2 weeks and if they fulfil the inclusion 
and exclusion criteria, they are formally consented and 
enrolled in the study. For the TAKeOFF sites, partici-
pants consent for screening and treatment together prior 
to the first screening procedures. Additionally, TAKeOFF 
study participants are asked to give consent for stor-
age, shipment and re-utilization of the samples (blood, 
urine, saliva) taken during the conduct of the trial. Prior 
to enrolment all subjects are provided with training 
on regular limb hygiene and given the necessary sup-
plies; compliance is assessed throughout treatment and 
follow-up using a questionnaire specifically developed 
for the study and additional training given at intervals 
to reinforce compliance. Baseline measurements of lym-
phoedema and laboratory parameters are made prior to 
starting treatment. A quality of life (QoL) assessment is 
Table 4 Staging of podoconiosis lymphoedema (after Tekola et al. (2008) [12])
Stage Definition
1 Swelling reversible overnight: the swelling is not present when the patient first gets up in the morning
2 Below‑knee swelling that is not completely reversible overnight; if present, knobs/bumps are below the ankle ONLY. Persistent swelling that 
does not reach above the knee. If knobs or bumps are seen or felt, they are only present below the ankle, NOT above the ankle
3 Below‑knee swelling that is not completely reversible overnight; knobs/bumps present above the ankle. Persistent swelling that does not reach 
above the knee. Knobs or bumps can be seen or felt above the ankle as well as below
4 Above‑knee swelling that is not completely reversible overnight; knobs/bumps present at any location. Persistent swelling that is present above 
the knee.
Knobs or bumps can be seen or felt at any place on the foot or leg
5 Joint fixation; swelling at any place in the foot or leg. The ankle or toe joints becomes fixed and difficult to flex or dorsiflex. This may be accom‑
panied by apparent shortening of the toes
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also performed using a simplified version of the 12-item 
Self-Reporting World Health Organization Disability 
Assessment Schedule (WHODAS) 2.0 [14, 15]. Addition-
ally, in Cameroon depression is being assessed in patients 
with podoconiosis [16].
Treatments were randomized prior to the study start 
and subjects were entered sequentially to receive pla-
cebo or doxycycline 200 mg (or if appropriate the lower 
100 mg dose) daily for six weeks. Participants are regu-
larly monitored during the six-week treatment period to 
collect safety information, to conduct pregnancy tests in 
women of childbearing potential and to issue new drug 
supplies. The subjects are assessed for lymphoedema 
measurements at 6, 12, 18 and 24 months after starting 
treatment as indicated in Additional file 4: Table S1.
The process of conducting subject visits varies from site 
to site and depends on the nature of the site and the dis-
tance from the Principal Investigator’s primary base. This 
varies from subjects travelling to the base hospital as in 
India where the subjects generally live close to the hospi-
tal, through a mixture of home visits during treatment and 
hospital visits for lymphoedema assessments (Sri Lanka), to 
fully field based investigations in villages (Mali, Ghana and 
Tanzania) where the study sites can be many hours travel 
from the primary base. All sites have developed a locally 
appropriate means of follow-up for participants who fail to 
attend scheduled visits, so that loss to follow-up would be 
kept to a minimum over the two years of the study.
Data collection
It was decided early during study development to aim 
to collect all data electronically using a laptop computer 
system that could transmit the data to data managers 
and subsequently to a central database. The REDCap 
tool (https ://www.proje ct-redca p.org/, REDCap Consor-
tium Emory University, Atlanta, USA) that was chosen 
provides an intuitive interface for validated data entry, 
audit trails for tracking data manipulation and export, 
automated export procedures for download to common 
statistical packages and the ability to import data from 
external sources [17, 18]. Data entry screens were devel-
oped in English and, for Mali, in English and French. 
Because of the nature of some of the sites and the need to 
maintain primary records it was decided that data would 
be initially entered onto paper Case Record Forms (CRFs) 
and subsequently entered onto the REDCap database by 
double data entry in all centres other than Mali. How-
ever, laptops are the primary source of data repository 
for the LymphaTech scans, ultrasound scans and digital 
photographs which are directly downloaded. To ensure 
linkage between individual patient CRFs, laboratory data, 
LymphaTech and other acquired data are all identified by 
bar-coding or the individual number of the participants 
which are composed of the country code, village number 
and number of the individual.
Statistical considerations
The study was designed to demonstrate that adjunctive 
doxycycline is superior to standardized hygiene meas-
ures. The main outcome of the study therefore assesses 
whether there is a difference between the doxycycline 
and placebo groups regarding the proportion of partici-
pants with initial stage 1–3 whose lymphoedema grade 
did not progress (their lymphoedema grade decreased or 
remained the same) at 24 months using a two-sided Fish-
er’s exact test at an α-level of 5%.
From the beginning, the data from the Mand study [7] 
were key in determining the numbers to be enrolled since 
no other evaluable data existed. In that study, progression 
of lymphedema occurred in 55% of the placebo (hygiene 
only) group compared to progression in 5% of the active 
(doxycycline plus hygiene) group. However, since in the 
present study a greater emphasis is being placed on a reg-
ular hygiene protocol together with frequent checks on 
adherence and proper application, it was expected that 
progression in a hygiene-only group might be less pro-
nounced and a progression in 25% might be expected for 
those on placebo (plus hygiene). Additionally, we chose 
to individually power each site since the geographical 
and cultural circumstances in each site were different and 
variations could preclude combination of the data.
Utilizing these estimates and assumptions, we calcu-
lated that 70 participants per arm would be required to 
see a statistical difference between the two groups with a 
significance level of 5% and with 95% power. A drop-out 
rate of < 30% over the two years was expected, so that a 
population of 100 patients in each of the two arms pro-
vided an appropriate trial size for the 3 LEDoxy study 
sites and the TAKeOFF podoconiosis trial. In the TAKe-
OFF studies where two active intervention dosages were 
being evaluated, and with the same expected progression 
in the placebo arm, a larger number was required, result-
ing in 120 subjects per arm (subsequent design with a 
power of 95% for the comparison of doxycycline 200 mg 
vs placebo and a power of 81% for the comparison of dox-
ycycline 100 mg vs placebo if the progression in the dox-
ycycline 100  mg group is ≤ 8%), again allowing for 30% 
loss to follow-up.
In addition to assessing progression of lymphoedema 
grade at 24 months, models that incorporate methods for 
analysing repeated measures will be used to determine 
whether differences in the measurement endpoints exist 
between study groups over time. Study group and time 
will be the main effects of the models, and if necessary, 
study sites will be included as blocking factors to account 
for site differences. All possible baseline characteristics, 
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e.g. sex, age, race, baseline clinical data, will be evalu-
ated for consideration of covariates. Analyses will be 
structured to include assessments of differences between 
12- 18- and 24-month outcomes within the repeated 
measures design.
Secondary endpoints will also be assessed to determine 
the impact of doxycycline treatment on other aspects of 
lymphoedema. In addition to assessing the lack of pro-
gression of lymphoedema at 24 months, the lack of pro-
gression at 12 and 18 months after treatment onset will 
also be assessed. In addition to the primary outcome, it 
is most important to evaluate the improvement of lym-
phoedema grades at the different time points (compari-
son of the proportion of decreased lymphoedema vs the 
ones that increased or did not change). This will also 
be additionally evaluated using methods for repeated 
measurements (as described above for the primary out-
come). As a third possibility to evaluate the main out-
come of lymphoedema stage changes, the three outcomes 
(improvement, no change or progression of lymphoe-
dema stages) will be considered separately and analysed 
accordingly.
The change in the circumference of the affected limb 
from baseline as measured by both tape-measure and by 
the Lymphatech scanner, is a secondary outcome. The 
Lymphatech scanner data will also be used to assess the 
change in limb volume from baseline to follow-up. Data 
on acute dermatolymphadenitis (ADLA) attacks are col-
lected every two months after treatment onset. Reduc-
tion in the frequency of ADLA attacks will be evaluated 
from baseline to follow-up. Changes in skin thickness 
at 12 and 24  months compared to baseline will also be 
assessed in the sites where ultrasound measurements of 
skin thickness were collected (LEDoxy sites).
Discussion
Although the original Mand study design was avail-
able, development of this protocol required a consid-
erable amount of time to ensure that the two segments 
(LEDoxy and TAKeOFF) were aligned in their think-
ing and also ensuring that all the potential sites were 
equipped and capable of conducting all the elements of 
the study. Despite all proposed study sites having consid-
erable experience in clinical trials, only the investigators 
in Ghana had any prior experience with the tools to be 
used in this study. Thus, site visits and audits were nec-
essary to ensure all the necessary facilities were present, 
not only at the base but also at proposed field sites, and 
that they could conduct the study to satisfy International 
Conference on Harmonization: Good Clinical Practices 
(ICH-GCP) requirements. One of the problems faced by 
the teams is the climatic and political instability of some 
locations, such that visits had to be delayed, often for a 
considerable amount of time. For example, the India 
study start was delayed because of severe flooding.
The original concept was to establish a protocol that 
would replicate the Mand study but with larger numbers. 
It was originally conceived as a multi-centre investigation 
with identical evaluations at each site, but it was soon 
apparent that the differences in the sites and the com-
parison of efficacy of high and low doxycycline regimens 
at two of the TAKeOFF sites would require each site to 
be individually powered. This resulted in essentially six 
separate protocols built around a common structure.
These double-blind studies required sourcing of appro-
priate active and placebo and took a considerable time. 
An initial source failed compliance testing when the 
materials were shipped by sea without any temperature 
protection and had to be destroyed. A second source was 
found that was only able to manufacture doxycycline, and 
the placebo had to be made by Piramal (UK). This had to 
be fitted into the production schedules of the company 
who obtained the necessary tablet punches to match the 
active. All the quality controls required for Good Manu-
facturing Practices (GMP) compliance were undertaken. 
As a result, production of enough material for the study 
took approximately one year before the final blister pack-
ing and labelling could be undertaken. Blister design also 
was an issue since the blister packs had to allow for dif-
ferent dose regimens and be able to be produced under 
GMP conditions.
There were significant delays in getting ethics approval 
for the studies in some countries and further delays in 
obtaining the necessary import licences for the supplies, 
without which the drugs could not be sent to the sites. In 
Ghana for instance, the site needed three ethical approv-
als from KNUST IRB, Ghana Health Service and Ghana 
FDA before the trial could commence. Synchronising the 
protocol from three different ethical bodies in the same 
country was a challenge. Frequent contact between the 
manufacturers and the countries was required to ensure 
that all documentation was in place ahead of air freight-
ing of the drugs, with almost a year passing between sup-
ply to the first and the last sites.
The evaluation tools used for the measurement of lym-
phoedema at the time of initial protocol design were gen-
erally very simple but subject to investigator accuracy to 
make them reproducible. For example, the measurement 
of leg circumference two centimetres above or below the 
original measurement point could completely mask any 
real changes. Ultrasound measurement of skin thick-
ness over the median and lateral malleolus of affected 
limbs was used in the original study and was included in 
the protocol. In practice it is very time consuming to get 
reproducible results and the method becomes a problem 
when large numbers of patients need to be evaluated. 
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Therefore, this evaluation was removed from the TAKe-
OFF protocols. It was fortuitous that the LymphaTech 
technology became available during protocol develop-
ment and appeared to offer significant benefits in speed 
of evaluation and elimination of investigator bias. After 
some discussion the method was incorporated into the 
protocol and the LymphaTech team has worked closely 
with the sites to train operators, developed and improve 
standard operating procedures and troubleshooting 
manuals. A study validating the LymphaTech scanner in 
Sri Lanka was done expressly for the purpose of examin-
ing the reliability of the tools to be used in LEDoxy and 
was funded by USAID under the umbrella of the LEDoxy 
grant [13].
Conclusions
This paper describes the conceptualisation, initial design 
and development of a multi-site protocol to determine 
whether adjunctive doxycycline given for six weeks pro-
vides benefit over standard care hygiene in patients with 
lymphoedema caused by lymphatic filariasis or podo-
coniosis. There have been numerous hurdles to be over-
come before the first patients could be enrolled in 2018 
and the first efficacy data will not be available until early 
2021. By providing the information on the protocols in 
use at an early stage we hope that those involved in the 
management of lymphoedema in endemic areas will 
begin to think about what else may be needed before a 
treatment, if successful, is incorporated into practice. If 
additional work is to be undertaken, then it is important 
that protocol development start well in advance to avoid 
the not inconsiderable delays that we have experienced 
in implementing the current work. We believe that the 
present design has the potential to answer the overall 
question and should provide detail on the efficacy of the 
intervention, the size of the benefit and evidence of the 
safety and tolerability of long-term doxycycline in areas 
where lymphatic filariasis and podoconiosis are endemic.
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